Shots:
- The P-IIIa STEP 4 trial involves assessing the safety and efficacy of Semaglutide (2.4 mg, SC, qw) vs PBO in adults with obesity for 68wks. The participants who reached the maintenance dose of semaglutide, during a 20wks. run-in period were randomized to either continue treatment with the therapy or switch to PBO for 48wks.
- Results: mean weight loss of 7.9% from week 20 to 68; patients regained 6.9% body weight who were switched to PBO; ETD ( -14.8%), patients lost 17.4% of their weight who stayed on semaglutide throughout 68wks. trial
- Semaglutide is an analogue of the human GLP-1 hormone, currently under investigation for chronic weight management and is under FDA and EMA’s review
Click here to read full press release/ article | Ref: PRNewswire | Image: SCRIP Intelligence
The post Novo Nordisk Presents Results of Semaglutide in P-IIIa STEP 4 Trial to Treat Obesity at ENDO 2021 first appeared on PharmaShots.
